Zeke Capital Advisors LLC boosted its stake in Danaher Co. (NYSE:DHR) by 67.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 17,463 shares of the conglomerate’s stock after buying an additional 7,026 shares during the period. Zeke Capital Advisors LLC’s holdings in Danaher were worth $1,621,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the company. Raymond James Financial Services Advisors Inc. boosted its holdings in shares of Danaher by 1.7% in the third quarter. Raymond James Financial Services Advisors Inc. now owns 70,541 shares of the conglomerate’s stock worth $6,051,000 after buying an additional 1,193 shares during the period. Crossmark Global Holdings Inc. purchased a new stake in shares of Danaher in the third quarter worth approximately $6,233,000. Lee Danner & Bass Inc. lifted its position in shares of Danaher by 50.5% in the third quarter. Lee Danner & Bass Inc. now owns 4,142 shares of the conglomerate’s stock worth $355,000 after purchasing an additional 1,390 shares in the last quarter. Bainco International Investors raised its position in Danaher by 9.5% during the third quarter. Bainco International Investors now owns 61,977 shares of the conglomerate’s stock valued at $5,316,000 after acquiring an additional 5,387 shares in the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in Danaher by 2.8% during the third quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 1,859,891 shares of the conglomerate’s stock valued at $159,541,000 after acquiring an additional 51,495 shares in the last quarter. Institutional investors own 77.66% of the company’s stock.
In related news, SVP Angela S. Lalor sold 42,988 shares of the business’s stock in a transaction that occurred on Friday, February 2nd. The stock was sold at an average price of $102.29, for a total value of $4,397,242.52. Following the completion of the transaction, the senior vice president now directly owns 82,008 shares in the company, valued at approximately $8,388,598.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Daniel L. Comas sold 62,989 shares of the business’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $101.96, for a total value of $6,422,358.44. Following the completion of the transaction, the chief financial officer now owns 227,805 shares of the company’s stock, valued at $23,226,997.80. The disclosure for this sale can be found here. Insiders have sold a total of 313,260 shares of company stock valued at $31,657,786 over the last 90 days. Corporate insiders own 12.20% of the company’s stock.
Shares of Danaher stock traded down $2.56 during trading on Friday, hitting $96.66. 1,803,876 shares of the company were exchanged, compared to its average volume of 2,119,292. The firm has a market capitalization of $69,212.84, a P/E ratio of 23.99, a PEG ratio of 2.08 and a beta of 1.03. Danaher Co. has a 1-year low of $78.97 and a 1-year high of $104.82. The company has a current ratio of 1.43, a quick ratio of 1.05 and a debt-to-equity ratio of 0.39.
Danaher (NYSE:DHR) last posted its earnings results on Tuesday, January 30th. The conglomerate reported $1.19 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.16 by $0.03. The company had revenue of $5.09 billion during the quarter, compared to analyst estimates of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period in the previous year, the company earned $1.05 EPS. research analysts anticipate that Danaher Co. will post 4.38 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Stockholders of record on Thursday, March 29th will be given a dividend of $0.16 per share. This is a positive change from Danaher’s previous quarterly dividend of $0.14. This represents a $0.64 annualized dividend and a dividend yield of 0.66%. The ex-dividend date of this dividend is Wednesday, March 28th. Danaher’s payout ratio is presently 15.88%.
A number of research firms have recently commented on DHR. ValuEngine raised shares of Danaher from a “hold” rating to a “buy” rating in a research report on Monday, April 2nd. Zacks Investment Research downgraded shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday, March 26th. Credit Suisse Group raised their price objective on shares of Danaher from $106.00 to $108.00 and gave the stock an “outperform” rating in a research note on Tuesday, March 13th. Deutsche Bank decreased their price target on shares of Danaher from $114.00 to $107.00 and set a “buy” rating on the stock in a research note on Thursday, March 1st. Finally, Barclays assumed coverage on Danaher in a report on Thursday, February 15th. They set an “overweight” rating and a $110.00 price objective for the company. One analyst has rated the stock with a sell rating, five have assigned a hold rating, sixteen have assigned a buy rating and one has assigned a strong buy rating to the company. Danaher presently has an average rating of “Buy” and an average target price of $102.23.
COPYRIGHT VIOLATION NOTICE: “Danaher Co. (DHR) Shares Bought by Zeke Capital Advisors LLC” was posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/04/07/zeke-capital-advisors-llc-boosts-stake-in-danaher-co-dhr.html.
Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The company's Life Sciences segment provides laser scanning, compound, surgical, and other stereo microscopes. This segment also offers filtration, separation, and purification technologies to the biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial sectors.
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.